Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes
Cancer Reports · 2023
DOI: 10.1002/cnr2.1821 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Reports, 2023. Verfasst von Vivek Chavda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, India. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Hepatitis C. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 234 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death worldwide. The incidence of HCC is affected by genetic and non‐genetic factors. Genetically, mutations in the genes, tumor protein P53 (TP53), catenin beta 1 (CTNNB1), AT‐rich interaction domain 1A (ARIC1A), cyclin dependent kinase inhibitor 2A (CDKN2A), mannose 6‐phosphate (M6P), smooth muscle action against decapentaplegic (SMAD2), retinoblastoma gene (RB1), cyclin D, antigen presenting cells (APC), AXIN1, and E‐cadherin, have been shown to contribute to the occurrence of HCC. Non‐genetic factors, including alcohol consumption, exposure to aflatoxin, age, gender, presence of hepatitis B (HBV), hepatitis C (HCV), and non‐alcoholic fatty liver disease (NAFLD), increase the risk of HCC. Recent Findings The severity of the disease and its occurrence vary based on geographical location. Furthermore, men and minorities have been shown to be disproportionately affected by HCC, compared with women and non‐minorities. Ethnicity has been reported to significantly affect tumorigenesis and clinical outcomes in patients diagnosed with HCC. Generally, differences in gene expression and/or the presence of comorbid medical diseases affect or influence the progression of HCC. Non‐Caucasian HCC patients are significantly more likely to have poorer survival outcomes, compared to their Caucasian counterparts. Finally, there are a number of factors that contribute to the success rate of treatments for HCC.
Conclusion
Assessment and treatment of HCC must be consistent using evidence‐based guidelines and standardized outcomes, as well as international clinical practice guidelines for global consensus. Standardizing the assessment approach and method will enable comparison and improvement of liver cancer research through collaboration between researchers, healthcare providers, and advocacy groups. In this review, we will focus on discussing epidemiological factors that result in deviations and changes in treatment approaches for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, India.
- Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Ohio, USA.
- Pharmacy Section, L M College of Pharmacy, Ahmedabad, India.
- Department of Pharmacology, L M College of Pharmacy, Ahmedabad, India.
- PharmD Section, L M College of Pharmacy, Ahmedabad, India.
- Department of Pharmaceutical Sciences, College of Pharmacy, St. John's University, New York, New York, USA.
ORCID-Profile: Amit K Tiwari
Zitieren
APA
Chavda, V., Zajac, K. K., Gunn, J. L., Balar, P., Khadela, A., Vaghela, D., Soni, S., Ashby, C. R., & Tiwari, A. K. (2023). Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes. Cancer Reports. https://doi.org/10.1002/cnr2.1821
Vancouver
Chavda V, Zajac KK, Gunn JL, Balar P, Khadela A, Vaghela D, et al. Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes. Cancer Reports. 2023. doi:10.1002/cnr2.1821
BibTeX
@article{Chavda2023,
author = {Chavda, Vivek and Zajac, Kelsee K and Gunn, Jenna Lynn and Balar, Pankti and Khadela, Avinash and Vaghela, Dixa and Soni, Shruti and Ashby, Charles R and Tiwari, Amit K},
title = {Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes},
journal = {Cancer Reports},
year = {2023},
doi = {10.1002/cnr2.1821}
}
EUVIMED